Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2022 07:00 ET | Source: SPHERICAL INSIGHTS LLP

Global Beta-Thalassemia Market Size to grow USD 823.1 Million by 2030 | CAGR of 8%; Spherical Insights & Consulting

New York, United States , Oct. 24, 2022 (GLOBE NEWSWIRE) -- According to a research report published by Spherical Insights & Consulting, the Global Beta- Thalassemia Market Size to grow from USD...
February 10, 2022 07:00 ET | Source: Imara, Inc.

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
July 13, 2021 22:58 ET | Source: Imara, Inc.

Imara Announces Pricing of Public Offering

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...
May 04, 2021 07:00 ET | Source: Imara, Inc.

Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights

BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
November 17, 2020 07:00 ET | Source: Imara, Inc.

Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory

BOSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
November 05, 2020 07:00 ET | Source: Imara, Inc.

Imara Reports Third Quarter 2020 Financial Results and Business Highlights

Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia IMR-687 granted Orphan Drug designation from European Commission for sickle cell disease ...
October 16, 2020 07:00 ET | Source: Imara, Inc.

Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia

BOSTON, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
September 02, 2020 07:00 ET | Source: Imara, Inc.

Imara to Present at Upcoming Investor Conferences

BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
August 14, 2020 07:00 ET | Source: Imara, Inc.

Imara Reports Second Quarter 2020 Financial Results and Business Highlights

Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial Reported Phase 2a interim safety and...
August 13, 2020 16:01 ET | Source: Imara, Inc.

Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease

BOSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...

Next Page keyboard_arrow_right